PuSH - Publikationsserver des Helmholtz Zentrums München

Hoffmann, C.* ; Gerber, P.A.* ; Cavelti-Weder, C.* ; Licht, L.* ; Kotb, R.* ; Al Dweik, R.* ; Cherfane, M.* ; Bornstein, S.R.* ; Perakakis, N.

Liver, NAFLD and COVID-19.

Horm. Metab. Res. 54, 522-531 (2022)
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Coronavirus disease 2019 (COVID-19) is characterized by a wide clinical spectrum that includes abnormalities in liver function indicative of liver damage. Conversely, people with liver diseases are at higher risk of severe COVID-19. In the current review, we summarize first the epidemiologic evidence describing the bidirectional relationship between COVID-19 and liver function/liver diseases. Additionally, we present the most frequent histologic findings as well as the most important direct and indirect mechanisms supporting a COVID-19 mediated liver injury. Furthermore, we focus on the most frequent liver disease in the general population, non-alcoholic or metabolic-associated fatty liver disease (NAFLD/MAFLD), and describe how COVID-19 may affect NAFLD/MAFLD development and progression and conversely how NAFLD/MAFLD may further aggravate a COVID-19 infection. Finally, we present the long-term consequences of the pandemic on the development and management of NAFLD.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Covid-19 ; Liver ; Mafld ; Nafld ; Sars-cov-2
ISSN (print) / ISBN 0018-5043
e-ISSN 1439-4286
Quellenangaben Band: 54, Heft: 8, Seiten: 522-531 Artikelnummer: , Supplement: ,
Verlag Thieme
Begutachtungsstatus Peer reviewed
Institut(e) Institute for Pancreatic Beta Cell Research (IPI)
Institute of Diabetes Research and Metabolic Diseases (IDM)